Working… Menu
Trial record 97 of 454 for:    DICLOFENAC

Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for Knee OA Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00484120
Recruitment Status : Completed
First Posted : June 8, 2007
Last Update Posted : August 2, 2011
Information provided by:

Brief Summary:
This study valuates the safety and efficacy of treatment with 3% Diclofenac Nano-Emulsion Cream versus Placebo in subjects with osteoarthritis of the knee.

Condition or disease Intervention/treatment Phase
Osteoarthritis of the Knee Drug: 3%-Diclofenac-Nano-Emulsion Cream Drug: Placebo cream Phase 2

Detailed Description:
This will be a multi-center, double-blind, placebo-controlled, multiple-dose, parallel treatment study. A total of 126 subjects will be randomized to receive either 3%-Diclofenac-NE cream or a placebo cream respectively. Following screening and a washout period from previous treatments subjects will be enrolled and will self-apply the study medication. During the study, subjects will apply 3%-Diclofenac-NE or placebo cream three times daily for 28 days and complete a home-diary. Subjects will visit the clinic at mid-treatment for a follow up examination and again for a final examination at the end of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Proof-of Concept Study to Evaluate the Safety and Analgesic Efficacy of Topical 3%-Diclofenac-Nano-Emulsion Cream Versus Placebo for Knee Osteoarthritis
Study Start Date : June 2007
Actual Primary Completion Date : November 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: 1
3% Diclofenac NE cream
Drug: 3%-Diclofenac-Nano-Emulsion Cream
3%-Diclofenac-Nano-Emulsion Cream

Placebo Comparator: 2 Drug: Placebo cream
Placebo cream

Primary Outcome Measures :
  1. Analgesic activity as measured by the WOMAC pain subscale. [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Patient's daily pain assessment in the home diary. [ Time Frame: 1 month ]
  2. Pain on walking. [ Time Frame: 1 month ]
  3. Safety and Tolerability. [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females 50 years of age and above.
  2. Patients with primary osteoarthritis in at least a single knee joint, grade 2 or 3 based on the Kellgren and Lawrence classification system.
  3. Radiographic evidence consistent with OA carried out within the 6 months before screening.
  4. Pain should have been present for at least half of the days in the previous month and for at least 48h prior to the screening visit.
  5. Eligible subjects must have used an oral, topical or rectal NSAID within the past 6 months before screening.
  6. At baseline, after a 1 week withdrawal period of analgesic/anti-inflammatory medications, subjects should have a flare of pain.
  7. Able to read, comprehend, and sign the consent form.
  8. Examined by the authorized physician and medically cleared to participate in the study.
  9. In general good health and have no contraindications to any of the investigational medicinal products.

Exclusion Criteria:

  1. Secondary osteoarthritis.
  2. Presence of a serious or unstable medical condition (e.g., malignancy, severe neurological impairment or uncontrolled hypertension) or poor general health interfering with compliance or assessment at the study physician's discretion.
  3. OA causing significant pain in any joint other than the knees.
  4. Any other rheumatic or non-rheumatic joint disease or any other painful condition within the past month (e.g. fibromyalgia).
  5. Knee surgery or other knee trauma at any time during the previous year or subjects for whom a treatment is planned within the study period that could alter the degree or nature of pain (e.g. arthroscopic techniques, osteotomy, joint replacement surgery etc.).
  6. Active or history of gastrointestinal ulceration or bleeding within the past 5 years.
  7. Presence of a significant active psychiatric disorder including major depression or subjects receiving anti-psychotic medication.
  8. Existence of any dermatological condition on the knee.
  9. Subjects with disabling congestive heart failure (CHF), angina, pulmonary disease.
  10. Clinically significant abnormal blood results.
  11. Subjects cannot have had an arthrocentesis prior or during the study.
  12. Concomitant treatment with physical and/or occupational therapy.
  13. Prior use of any type of NSAID or other analgesic before taking the first dose of investigational medicinal product. Rescue treatment will be allowed during the study
  14. Change in sedative or CNS/psychotropic agent within the past month.
  15. Chronic treatment with anticoagulants (e.g. Warfarin).
  16. Subjects under treatment with corticosteroids.
  17. Subjects using topical analgesics including OTC products.
  18. Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test.
  19. Active alcoholism or substance abuse.
  20. Has taken an investigational drug or has used an investigational device within the past 30 days.
  21. History of hypersensitivity and/or idiosyncrasy to diclofenac or excipients employed in this study, aspirin or other NSAIDS.
  22. Has previously been entered into this study.
  23. Any condition that in the investigator's judgement precludes participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00484120

Layout table for location information
Barzilai Medical Center
Ashkelon, Israel, 78278
Rambam Medical Center
Haifa, Israel, 9602
Rabin Medical Center
Petah Tikva, Israel, 49100
Sourasky Medical Center
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Eisenberg Elon, MD Rambam Health Care Campus

Layout table for additonal information
Responsible Party: Clinical Team, Pharmos Ltd Identifier: NCT00484120     History of Changes
Other Study ID Numbers: PH-2007-2
First Posted: June 8, 2007    Key Record Dates
Last Update Posted: August 2, 2011
Last Verified: August 2011
Keywords provided by Pharmos:
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action